^
    Back
    Association details:
    Biomarker:TMB-H
    Cancer:Melanoma
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor) +
    Cotellic (cobimetinib) (MEK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Ann Oncol
    Title:

    Cobimetinib plus atezolizumab in BRAF V600 wild-type melanoma: primary results from the randomized phase 3 IMspire170 study

    Published date:
    12/10/2020
    Excerpt:
    IMspire170 was an international, randomized, open-label, phase 3 study.Patients were randomized 1:1 to receive cobimetinib (60 mg, days 1-21) plus anti-programmed death-ligand 1 atezolizumab (840 mg every 2 weeks) in 28-day cycles or anti-programmed death-1 pembrolizumab (200 mg every 3 weeks)...In exploratory biomarker analyses, higher tumor mutational burden was associated with improved clinical outcomes in both treatment arms.
    DOI:
    10.1016/j.annonc.2020.12.004
    Trial ID:
    IMspire170